Anthony H. Kim is the Chief Financial Officer at Marker Therapeutics.
As the Chief Financial Officer of Marker Therapeutics, the total compensation of Mr Kim at Marker Therapeutics is $550,906. There are 1 executives at Marker Therapeutics getting paid more, with Peter L. Hoang MBA having the highest compensation of $625,882.
Mr Kim is 45, he's been the Chief Financial Officer of Marker Therapeutics since . There are 2 older and 2 younger executives at Marker Therapeutics. The oldest executive at Marker Therapeutics, Inc. is Michael J. Loiacono, 55, who is the Chief Accounting Officer, Treasurer & Sec..
Anthony's mailing address filed with the SEC is C/O MARKER THERAPEUTICS, INC., 3200 SOUTHWEST FREEWAY, SUITE 2500, HOUSTON, TX, .
Over the last 6 years, insiders at Marker Therapeutics have traded over $0 worth of Marker Therapeutics stock and bought 60,748,562 units worth $106,570,272 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, Marker Therapeutics executives and independent directors trade stock every 38 days with the average trade being worth of $9,934,177. The most recent stock trade was executed by Frederick Gerald Wasserman on 18 May 2021, trading 10,000 units of MRKR stock currently worth $24,100.
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Marker Therapeutics executives and other stock owners filed with the SEC include: